Market Research Logo

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016

Introduction
Global Markets Direct Report Coverage
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) Overview
Therapeutics Development
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Stage of Development
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Therapy Area
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Indication
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Companies
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Products under Development by Universities/Institutes
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Companies Involved in Therapeutics Development
Amgen Inc.
Advinus Therapeutics Ltd.
Astellas Pharma Inc.
Caldan Therapeutics Limited
Connexios Life Sciences Pvt. Ltd.
Daiichi Sankyo Company, Limited
Hyundai Pharmaceutical Co., Ltd.
Japan Tobacco Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Drug Profiles
AM-1638 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-3189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-6226 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-2034178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-2575959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CNX-011-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-1558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HD-6277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTT-851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GPR40 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR40 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TUG-770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Dormant Projects
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Discontinued Products
Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Featured News & Press Releases
Apr 10, 2012: Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU -CEO
Jun 27, 2011: Connexios Life Science Presents Preclinical Data On CNX-011-67 At American Diabetes Association Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Amgen Inc., H1 2016
Pipeline by Advinus Therapeutics Ltd., H1 2016
Pipeline by Astellas Pharma Inc., H1 2016
Pipeline by Caldan Therapeutics Limited, H1 2016
Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016
Pipeline by Daiichi Sankyo Company, Limited, H1 2016
Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016
Pipeline by Japan Tobacco Inc., H1 2016
Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
Dormant Projects, H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) - Pipeline Review, H1 2016’, provides in depth analysis on Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1)
  • The report reviews Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G-Protein Coupled Receptor 40 or FFAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;